Utilizes a proprietary Click Activated Protodrugs Against Cancer (CAPAC®) platform to deliver cancer therapies by separating tumor-targeting binders from inert payloads, which are activated through in-vivo click chemistry at the tumor site. This approach increases the concentration of active drugs or radioisotopes at tumors while reducing systemic toxicity, improving treatment efficacy for patients with limited options.
Funding
$65.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EVNCNSWJFounders
Product
Problem
Current cancer therapies often lack precision, leading to systemic toxicity and limiting the amount of active drug that reaches the tumor. This can result in reduced treatment efficacy and significant side effects for patients. Less than 1% of administered drugs reach their intended target.
Solution
Shasqi utilizes its Click Activated Protodrugs Against Cancer (CAPAC®) platform to enhance cancer therapy delivery. This pre-targeting approach separates tumor-targeting binders from inert payloads, reuniting them at the tumor site via in-vivo click chemistry, a Nobel Prize-winning technology. The clickable binder selectively binds to the tumor, while the clickable payload, either a radioisotope or cancer drug, remains inert until it clicks with the binder. This activation process locks the radioisotope at the tumor or activates the chemotherapy payload, maximizing the active payload at the tumor while minimizing systemic toxicity.
Target Audience
The primary target audience includes patients with solid tumors who have limited effective treatment options, as well as oncologists and researchers seeking to improve cancer therapy efficacy and reduce toxicity.
Features
- CAPAC® platform separates tumor targeting from the payload, relying on chemistry for activation.
- In-vivo click chemistry enables precise drug activation at the tumor site.
- Modular design allows for the use of various payloads, including radioisotopes and chemotherapeutic drugs.
- Reduced systemic toxicity compared to traditional antibody-drug conjugates (ADCs) and targeted radiopharmaceutical approaches.
- Clinically validated platform with ongoing advancement of novel therapies.